Developer docs
API playgroundTry for free, no card

Search company profiles

Galaxy Diagnostics

Full company profile

uuid00025o7

Namestring
Galaxy Diagnostics
Legal namestring
Galaxy Diagnostics, Inc.
Websiteurl
galaxydx.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

Galaxy Diagnostics, Inc. (DBA Galaxy Dx) is a CLIA- and COLA-accredited specialty diagnostic laboratory headquartered in Research Triangle Park, North Carolina, focused exclusively on detecting stealth vector-borne pathogens—Bartonella, Borrelia (Lyme), and Babesia—that evade conventional diagnostics through immune suppression and tissue persistence. The company combines direct detection (Digital PCR across 26,000 partitions offering up to 10x sensitivity vs standard PCR, plus Nanotrap® urine antigen capture licensed from Ceres Nanosciences) with indirect methods (a 4-species Bartonella IFA serology panel developed with North Carolina State University) and BAPGM™ culture enrichment. Core products include BBB Direct Detect™, Lyme Borrelia Direct Detect (Nanotrap®), Bartonella IgG Detect, the BAPGM™ enrichment culture, and the Suspected Tick-Borne Bundle. Tests are sold exclusively to licensed healthcare providers in 49 US states under a pre-payment cash-pay model with no insurance, Medicare, or Medicaid enrollment; patients receive superbills for self-submission. The company was founded in 2009, is led by CEO Nicole Bell (appointed June 2024), and is advancing a Lyme peptidoglycan diagnostic licensed from Virginia Tech/Dr. Brandon Jutras toward FDA submission via the LymeX Diagnostic Prize Challenge Phase 4.

Short descriptiontext

Galaxy Diagnostics is a CLIA-accredited specialty laboratory that detects stealth vector-borne pathogens (Bartonella, Borrelia, Babesia) via Digital PCR, Nanotrap® urine antigen testing, and 4-species IFA serology, serving licensed healthcare providers across 49 US states.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDurham, United States
HQ citystring
Durham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
infectious disease diagnostics, tick-borne disease testing, molecular diagnostic laboratory, vector-borne pathogen detection, specialty clinical laboratory
Industry3 codes
PRIMARYHLAFAMAD
Microbiology & Infectious Disease Testing Laboratories
SECONDARYHLAAALAN
Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays
SECONDARYHLAAALAB
Immunoassay Diagnostics (ELISA, chemiluminescence, serology)
NAICS code2 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
SIC code2 codes
  • Services-Medical Laboratories8071
  • Services-Testing Laboratories8734
Product category
Specialty Infectious Disease Diagnostics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Laboratory Testing Services
TypeOne Time License
Description

Galaxy Diagnostics offers CLIA-accredited laboratory-developed tests (LDTs) for vector-borne pathogens. Pre-payment is required for all orders. Accepted payment methods include major credit cards, checks, CareCredit, and Affirm (case-by-case BNPL). The company is not enrolled in insurance networks but provides superbills for self-submission to insurance providers. No Medicare or Medicaid enrollment.

galaxydx.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details2 tiers
1Test Kit and Specimen Collection
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Providers with accounts can order kits online. Test kits include requisition form, specimen collection instructions, patient consent form, and prepaid FedEx return shipping. Specimens billed upon arrival at lab.

galaxydx.com
2Panel Testing Discount
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Discounted panel pricing when multiple specimens (e.g., triple draw) are shipped together and received within 2 weeks of each other. 1-week extension available with email notification.

galaxydx.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Galaxy Diagnostics operates a CLIA- and COLA-accredited specialty reference laboratory that provides laboratory-developed diagnostic tests (LDTs) for stealth vector-borne pathogens, with primary focus on Bartonella and extending to Borrelia (Lyme disease) and Babesia. The company combines direct detection methods — Digital PCR and Nanotrap® urine antigen testing — with indirect detection (4-species Bartonella IFA serology) and BAPGM enrichment culture, delivering results to licensed healthcare providers through a HIPAA-compliant portal. Tests are sold exclusively to clinicians (MD, DO, NP, PA, ND with active NPI numbers), not directly to consumers, with the company licensed to operate in 49 U.S. states.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 6x higher positivity rates with digital PCR compared to standard qPCR (Maggi et al., Parasites & Vectors, 2024)
+5 more records
Product overview1 text field

Galaxy Diagnostics provides a CLIA-accredited diagnostic testing platform focused on stealth vector-borne pathogens (Bartonella, Borrelia, and Babesia) through three complementary testing modalities: Digital PCR (BBB Direct Detect™) for highly sensitive genus-level DNA detection across all three pathogens, Nanotrap® urine antigen testing (Lyme Borrelia Direct Detect) for non-invasive direct detection of Borrelia OspA antigen, and a 4-species Bartonella IgG IFA Serology Panel for immune response assessment. These products can be ordered individually or bundled as the Suspected Tick-Borne Bundle, and are supported by BAPGM™ enrichment culture for enhanced Bartonella detection. All tests are laboratory-developed tests (LDTs) validated in-house under CLIA regulations, with results delivered through a HIPAA-compliant provider portal.

Product and service6 records
1BBB Direct Detect™
CategoryMolecular diagnostic testing
Description

Digital PCR-based multiplexed assay detecting Bartonella, Babesia, and Borrelia at the genus level from blood samples, with option for serial triple-draw collection to improve detection of intermittently circulating pathogens. Sold to licensed healthcare providers.

2Lyme Borrelia Direct Detect – Nanotrap®
CategoryAntigen-based diagnostic testing
Description

Direct detection test using proprietary Nanotrap® particles to capture and concentrate Borrelia OspA antigen from urine, enabling earlier Lyme disease diagnosis without relying on antibody response. Sold to licensed healthcare providers.

3Bartonella IgG Detect
CategorySerology diagnostic testing
Description

Indirect immunofluorescence assay (IFA) serology panel detecting IgG antibodies against four Bartonella species (B. henselae, B. vinsonii berkhoffii, B. quintana, B. koehlerae), providing immune response insights and species-specific exposure confirmation. Sold to licensed healthcare providers.

4Suspected Tick-Borne Bundle
CategoryCombined diagnostic testing panel
Description

Comprehensive testing bundle combining BBB Direct Detect (digital PCR across three serial blood draws), Bartonella IgG Detect (serology for four species), and Lyme Borrelia Direct Detect (urine antigen testing) for patients with suspected tick-borne illness. Sold to licensed healthcare providers.

5Bartonella IFA Panel
CategorySerology diagnostic testing
Description

4-species IgG immunofluorescence assay panel covering B. henselae, B. vinsonii berkhoffii, B. quintana, and B. koehlerae, developed in partnership with North Carolina State University using clinical isolates. Sold to licensed healthcare providers.

6BAPGM™ Culture
CategoryPre-analytical enrichment service
Description

Proprietary Bartonella alpha-Proteobacteria Growth Medium enrichment culture for Bartonella species used prior to digital PCR testing, dramatically improving detection sensitivity by enriching bacterial growth before molecular confirmation. Sold to licensed healthcare providers.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-01-26
Description

Exclusive license agreement for Dr. Brandon Jutras's novel peptidoglycan diagnostic target for Lyme disease. Partnership aims to combine Galaxy's urine antigen detection technology with Virginia Tech's peptidoglycan research to develop more reliable early-stage Lyme diagnostics for FDA submission. Represents Galaxy's strategy to bridge academic discovery with real-world diagnostic access.

2Dr. Brandon L. Jutras
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Galaxy's first commercialization partner for Dr. Jutras's peptidoglycan diagnostic technology. Collaboration includes clinical sample evaluation and scientific validation required to support future assay development and regulatory pathways. Dr. Jutras is Associate Professor at Northwestern University Feinberg School of Medicine and internationally recognized expert in tick-borne bacterial infections.

galaxydx.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with NC State University's College of Veterinary Medicine for Bartonella research and diagnostic development. Dr. Edward Breitschwerdt serves as Chief Scientific Advisor and is a professor at NC State. Dr. Ricardo Maggi is a Research Professor directing research at NC State's Intracellular Pathogens Research Laboratory. The Bartonella IFA Panel was developed in partnership with NC State using clinical isolates.

Strategic tierCoreTypeTechnology or Integration
Description

Licensing partner for Nanotrap® particle technology. Ceres Nanosciences developed the proprietary Nanotrap® particles that capture and concentrate Borrelia OspA antigens from urine. Galaxy Diagnostics has optimized this technology for clinical use and real-world patient testing.

5Research and Testing Partners
Strategic tierMinorTypeOthers
Description

Galaxy Diagnostics offers pathogen testing services to research collaborators including: Bayer Animal Health, Idexx Reference Labs, Focus on Lyme, Duke University, University of Minnesota, University of Washington's Center for One Health Research, One Medicine Institute, and various drug development companies.

galaxydx.com
6Board of Directors Advisors
Strategic tierCoreTypeOthers
Description

Board includes leaders from Labcorp and Quest Diagnostics who help ensure what Galaxy builds works in the real world. Scientific Advisory Board includes Dr. Meghan Starolis (Quest Diagnostics), Dr. Suzanne Dale (LabCorp), Dr. John Aucott (Johns Hopkins University), Dr. Ross Boyce (UNC Chapel Hill).

galaxydx.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1IGeneX
TypeDirect peer
Description

IGeneX is a specialty reference laboratory in California offering tick-borne disease testing (Lyme, Babesia, Bartonella) via PCR, IFA serology, and immunoblot, serving the same functional/integrative medicine provider community as Galaxy. It is the closest direct competitor on Lyme and Bartonella specialty testing.

TypeDirect peer
Description

Vibrant Wellness (formerly Vibrant America) is a functional medicine specialty lab offering extensive serum, stool, and infectious disease panels (including tick-borne) ordered through integrative providers. It competes with Galaxy for the same practitioner-driven, self-pay testing volumes in the functional medicine channel.

TypeDirect peer
Description

Genova Diagnostics is a specialty laboratory focused on functional and integrative medicine testing (gastrointestinal, hormonal, genomic, and select infectious panels). It targets the same provider base and uses a similar direct-to-provider ordering model, making it a direct peer for clinical sales motion and test menu.

TypeDirect peer
Description

Doctor's Data is a specialty reference lab serving integrative and functional medicine practitioners with stool, toxic exposure, and infectious panels. It shares Galaxy's practitioner-direct distribution model and target buyer (naturopathic and integrative physicians).

TypeBroad incumbent
Description

Quest Diagnostics is one of the two largest U.S. clinical reference laboratories, offering broad infectious disease serology and PCR including Lyme and Babesia. While it does not specialize in stealth vector-borne testing, it is expanding specialty tick-borne panels and represents the incumbent Galaxy would compete against for mainstream Lyme testing volumes.

TypeBroad incumbent
Description

LabCorp is a leading global clinical laboratory network with broad infectious disease menu including tick-borne disease serology and PCR. As a broad incumbent with national phlebotomy and payer relationships, LabCorp is the natural strategic acquirer or distribution partner for Galaxy's specialty tick-borne diagnostic IP.

TypeBroad incumbent
Description

ARUP Laboratories is an academic reference laboratory affiliated with the University of Utah, providing esoteric infectious disease testing including Lyme and Bartonella. As a non-profit hospital-affiliated reference lab with strong academic credentials, ARUP competes for hospital-driven specialty Lyme testing.

TypeBroad incumbent
Description

Mayo Clinic Laboratories is a major academic reference laboratory offering esoteric infectious disease and vector-borne testing. It represents the established academic reference lab option for clinicians seeking specialty diagnostics and could either partner with or compete against Galaxy for hospital-based Lyme/Bartonella testing.

TypeOthers
Description

Ceres Nanosciences is the developer of Nanotrap particle technology, which Galaxy licenses for its Lyme Borrelia urine antigen test. As the upstream licensor, Ceres is an enabling ecosystem participant rather than a competitor but could become a strategic channel if it broadens its clinical diagnostics footprint.

TypeOthers
Description

Bay Area Lyme Foundation is a nonprofit research and advocacy organization supporting Lyme disease diagnostics and treatment; its venture philanthropy arm (Bay Area Lyme Ventures) made a strategic investment in Galaxy. It is an ecosystem/funder participant driving awareness, capital, and patient demand into Galaxy's market.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights9 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles20 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Galaxy Diagnostics

Specialty Infectious Disease Diagnosticsgalaxydx.com

Galaxy Diagnostics is a CLIA-accredited specialty laboratory that detects stealth vector-borne pathogens (Bartonella, Borrelia, Babesia) via Digital PCR, Nanotrap® urine antigen testing, and 4-species IFA serology, serving licensed healthcare providers across 49 US states.

What Galaxy Diagnostics does

Galaxy Diagnostics, Inc. (DBA Galaxy Dx) is a CLIA- and COLA-accredited specialty diagnostic laboratory headquartered in Research Triangle Park, North Carolina, focused exclusively on detecting stealth vector-borne pathogens—Bartonella, Borrelia (Lyme), and Babesia—that evade conventional diagnostics through immune suppression and tissue persistence. The company combines direct detection (Digital PCR across 26,000 partitions offering up to 10x sensitivity vs standard PCR, plus Nanotrap® urine antigen capture licensed from Ceres Nanosciences) with indirect methods (a 4-species Bartonella IFA serology panel developed with North Carolina State University) and BAPGM™ culture enrichment. Core products include BBB Direct Detect™, Lyme Borrelia Direct Detect (Nanotrap®), Bartonella IgG Detect, the BAPGM™ enrichment culture, and the Suspected Tick-Borne Bundle. Tests are sold exclusively to licensed healthcare providers in 49 US states under a pre-payment cash-pay model with no insurance, Medicare, or Medicaid enrollment; patients receive superbills for self-submission. The company was founded in 2009, is led by CEO Nicole Bell (appointed June 2024), and is advancing a Lyme peptidoglycan diagnostic licensed from Virginia Tech/Dr. Brandon Jutras toward FDA submission via the LymeX Diagnostic Prize Challenge Phase 4.

Galaxy Diagnostics firmographics

Firmographics
Name
Galaxy Diagnostics
Legal name
Galaxy Diagnostics, Inc.
Website
https://galaxydx.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Short description
Galaxy Diagnostics is a CLIA-accredited specialty laboratory that detects stealth vector-borne pathogens (Bartonella, Borrelia, Babesia) via Digital PCR, Nanotrap® urine antigen testing, and 4-species IFA serology, serving licensed healthcare providers across 49 US states.
Ownership category
akta.pro rank

Galaxy Diagnostics industry classification

Industry
Product category
Specialty Infectious Disease Diagnostics
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
SIC
Services-Medical Laboratories (8071), Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYHLAFAMAD
Microbiology & Infectious Disease Testing Laboratories
SECONDARYHLAAALAN
Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays
SECONDARYHLAAALAB
Immunoassay Diagnostics (ELISA, chemiluminescence, serology)

Keywords

  • Infectious disease diagnostics
  • Tick-borne disease testing
  • Molecular diagnostic laboratory
  • Vector-borne pathogen detection
  • Specialty clinical laboratory

Where Galaxy Diagnostics is headquartered

Location

Headquarters

HQ city
Durham
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Galaxy Diagnostics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Laboratory Testing Services: Galaxy Diagnostics offers CLIA-accredited laboratory-developed tests (LDTs) for vector-borne pathogens. Pre-payment is required for all orders. Accepted payment methods include major credit cards, checks, CareCredit, and Affirm (case-by-case BNPL). The company is not enrolled in insurance networks but provides superbills for self-submission to insurance providers. No Medicare or Medicaid enrollment.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goTest Kit and Specimen Collection
Unit PricingPay-as-you-goPanel Testing Discount

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Galaxy Diagnostics product offering

Product offering

Core offering

Galaxy Diagnostics operates a CLIA- and COLA-accredited specialty reference laboratory that provides laboratory-developed diagnostic tests (LDTs) for stealth vector-borne pathogens, with primary focus on Bartonella and extending to Borrelia (Lyme disease) and Babesia. The company combines direct detection methods — Digital PCR and Nanotrap® urine antigen testing — with indirect detection (4-species Bartonella IFA serology) and BAPGM enrichment culture, delivering results to licensed healthcare providers through a HIPAA-compliant portal. Tests are sold exclusively to clinicians (MD, DO, NP, PA, ND with active NPI numbers), not directly to consumers, with the company licensed to operate in 49 U.S. states.

Product overview

Galaxy Diagnostics provides a CLIA-accredited diagnostic testing platform focused on stealth vector-borne pathogens (Bartonella, Borrelia, and Babesia) through three complementary testing modalities: Digital PCR (BBB Direct Detect™) for highly sensitive genus-level DNA detection across all three pathogens, Nanotrap® urine antigen testing (Lyme Borrelia Direct Detect) for non-invasive direct detection of Borrelia OspA antigen, and a 4-species Bartonella IgG IFA Serology Panel for immune response assessment. These products can be ordered individually or bundled as the Suspected Tick-Borne Bundle, and are supported by BAPGM™ enrichment culture for enhanced Bartonella detection. All tests are laboratory-developed tests (LDTs) validated in-house under CLIA regulations, with results delivered through a HIPAA-compliant provider portal.

Differentiator

Problem solved

Functional benefit

Products and services

  • BBB Direct Detect™ Digital PCR-based multiplexed assay detecting Bartonella, Babesia, and Borrelia at the genus level from blood samples, with option for serial triple-draw collection to improve detection of intermittently circulating pathogens. Sold to licensed healthcare providers.
  • Lyme Borrelia Direct Detect – Nanotrap® Direct detection test using proprietary Nanotrap® particles to capture and concentrate Borrelia OspA antigen from urine, enabling earlier Lyme disease diagnosis without relying on antibody response. Sold to licensed healthcare providers.
  • Bartonella IgG Detect Indirect immunofluorescence assay (IFA) serology panel detecting IgG antibodies against four Bartonella species (B. henselae, B. vinsonii berkhoffii, B. quintana, B. koehlerae), providing immune response insights and species-specific exposure confirmation. Sold to licensed healthcare providers.
  • Suspected Tick-Borne Bundle Comprehensive testing bundle combining BBB Direct Detect (digital PCR across three serial blood draws), Bartonella IgG Detect (serology for four species), and Lyme Borrelia Direct Detect (urine antigen testing) for patients with suspected tick-borne illness. Sold to licensed healthcare providers.
  • Bartonella IFA Panel 4-species IgG immunofluorescence assay panel covering B. henselae, B. vinsonii berkhoffii, B. quintana, and B. koehlerae, developed in partnership with North Carolina State University using clinical isolates. Sold to licensed healthcare providers.
  • BAPGM™ Culture Proprietary Bartonella alpha-Proteobacteria Growth Medium enrichment culture for Bartonella species used prior to digital PCR testing, dramatically improving detection sensitivity by enriching bacterial growth before molecular confirmation. Sold to licensed healthcare providers.

Quantifiable outcome

  • 6x higher positivity rates with digital PCR compared to standard qPCR (Maggi et al., Parasites & Vectors, 2024)
  • +5 more outcomes

Companies that use Galaxy Diagnostics

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Galaxy Diagnostics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Galaxy Diagnostics partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Virginia TechcoreTechnology or Integration · 26 January 2026Exclusive license agreement for Dr. Brandon Jutras's novel peptidoglycan diagnostic target for Lyme disease. Partnership aims to combine Galaxy's urine antigen detection technology with Virginia Tech's peptidoglycan research to develop more reliable early-stage Lyme diagnostics for FDA submission. Represents Galaxy's strategy to bridge academic discovery with real-world diagnostic access.
  • Dr. Brandon L. JutrascoreStrategic or Co-development PartnerGalaxy's first commercialization partner for Dr. Jutras's peptidoglycan diagnostic technology. Collaboration includes clinical sample evaluation and scientific validation required to support future assay development and regulatory pathways. Dr. Jutras is Associate Professor at Northwestern University Feinberg School of Medicine and internationally recognized expert in tick-borne bacterial infections.
  • North Carolina State UniversitycoreStrategic or Co-development PartnerPartnership with NC State University's College of Veterinary Medicine for Bartonella research and diagnostic development. Dr. Edward Breitschwerdt serves as Chief Scientific Advisor and is a professor at NC State. Dr. Ricardo Maggi is a Research Professor directing research at NC State's Intracellular Pathogens Research Laboratory. The Bartonella IFA Panel was developed in partnership with NC State using clinical isolates.
  • Ceres NanosciencescoreTechnology or IntegrationLicensing partner for Nanotrap® particle technology. Ceres Nanosciences developed the proprietary Nanotrap® particles that capture and concentrate Borrelia OspA antigens from urine. Galaxy Diagnostics has optimized this technology for clinical use and real-world patient testing.
  • Research and Testing PartnersminorOthersGalaxy Diagnostics offers pathogen testing services to research collaborators including: Bayer Animal Health, Idexx Reference Labs, Focus on Lyme, Duke University, University of Minnesota, University of Washington's Center for One Health Research, One Medicine Institute, and various drug development companies.
  • Board of Directors AdvisorscoreOthersBoard includes leaders from Labcorp and Quest Diagnostics who help ensure what Galaxy builds works in the real world. Scientific Advisory Board includes Dr. Meghan Starolis (Quest Diagnostics), Dr. Suzanne Dale (LabCorp), Dr. John Aucott (Johns Hopkins University), Dr. Ross Boyce (UNC Chapel Hill).

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Galaxy Diagnostics competitors and assessment

Company assessment

Direct peers

  • IGeneX: IGeneX is a specialty reference laboratory in California offering tick-borne disease testing (Lyme, Babesia, Bartonella) via PCR, IFA serology, and immunoblot, serving the same functional/integrative medicine provider community as Galaxy. It is the closest direct competitor on Lyme and Bartonella specialty testing.
  • Vibrant Wellness: Vibrant Wellness (formerly Vibrant America) is a functional medicine specialty lab offering extensive serum, stool, and infectious disease panels (including tick-borne) ordered through integrative providers. It competes with Galaxy for the same practitioner-driven, self-pay testing volumes in the functional medicine channel.
  • Genova Diagnostics: Genova Diagnostics is a specialty laboratory focused on functional and integrative medicine testing (gastrointestinal, hormonal, genomic, and select infectious panels). It targets the same provider base and uses a similar direct-to-provider ordering model, making it a direct peer for clinical sales motion and test menu.
  • Doctor's Data: Doctor's Data is a specialty reference lab serving integrative and functional medicine practitioners with stool, toxic exposure, and infectious panels. It shares Galaxy's practitioner-direct distribution model and target buyer (naturopathic and integrative physicians).

Broad incumbents

  • Quest Diagnostics: Quest Diagnostics is one of the two largest U.S. clinical reference laboratories, offering broad infectious disease serology and PCR including Lyme and Babesia. While it does not specialize in stealth vector-borne testing, it is expanding specialty tick-borne panels and represents the incumbent Galaxy would compete against for mainstream Lyme testing volumes.
  • LabCorp: LabCorp is a leading global clinical laboratory network with broad infectious disease menu including tick-borne disease serology and PCR. As a broad incumbent with national phlebotomy and payer relationships, LabCorp is the natural strategic acquirer or distribution partner for Galaxy's specialty tick-borne diagnostic IP.
  • ARUP Laboratories: ARUP Laboratories is an academic reference laboratory affiliated with the University of Utah, providing esoteric infectious disease testing including Lyme and Bartonella. As a non-profit hospital-affiliated reference lab with strong academic credentials, ARUP competes for hospital-driven specialty Lyme testing.
  • Mayo Clinic Laboratories: Mayo Clinic Laboratories is a major academic reference laboratory offering esoteric infectious disease and vector-borne testing. It represents the established academic reference lab option for clinicians seeking specialty diagnostics and could either partner with or compete against Galaxy for hospital-based Lyme/Bartonella testing.

Others

  • Ceres Nanosciences: Ceres Nanosciences is the developer of Nanotrap particle technology, which Galaxy licenses for its Lyme Borrelia urine antigen test. As the upstream licensor, Ceres is an enabling ecosystem participant rather than a competitor but could become a strategic channel if it broadens its clinical diagnostics footprint.
  • Bay Area Lyme Foundation: Bay Area Lyme Foundation is a nonprofit research and advocacy organization supporting Lyme disease diagnostics and treatment; its venture philanthropy arm (Bay Area Lyme Ventures) made a strategic investment in Galaxy. It is an ecosystem/funder participant driving awareness, capital, and patient demand into Galaxy's market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights9 records

Customer concentration

Galaxy Diagnostics social profiles

Digital presence

Galaxy Diagnostics compliance and trust

Trust signal

Compliance3 records

Galaxy Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Galaxy Diagnostics leadership team

Management profile

Number of profiles

Profiles20 records

Galaxy Diagnostics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Galaxy Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Galaxy Diagnostics

What does Galaxy Diagnostics do?

Galaxy Diagnostics operates a CLIA- and COLA-accredited specialty reference laboratory that provides laboratory-developed diagnostic tests (LDTs) for stealth vector-borne pathogens, with primary focus on Bartonella and extending to Borrelia (Lyme disease) and Babesia. The company combines direct detection methods — Digital PCR and Nanotrap® urine antigen testing — with indirect detection (4-species Bartonella IFA serology) and BAPGM enrichment culture, delivering results to licensed healthcare providers through a HIPAA-compliant portal. Tests are sold exclusively to clinicians (MD, DO, NP, PA, ND with active NPI numbers), not directly to consumers, with the company licensed to operate in 49 U.S. states.

Is Galaxy Diagnostics a public or private company?

Galaxy Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Galaxy Diagnostics founded?

Galaxy Diagnostics was founded in 2009. It employs 11 to 50 people.

Where is Galaxy Diagnostics based?

Galaxy Diagnostics is headquartered in Durham, United States, in the North America region.

How does Galaxy Diagnostics make money?

One revenue line is on record: laboratory Testing Services.

Who are Galaxy Diagnostics's main competitors?

Direct peers on record are IGeneX, Vibrant Wellness, Genova Diagnostics and Doctor's Data. Broad incumbents are Quest Diagnostics, LabCorp, ARUP Laboratories and Mayo Clinic Laboratories. Others are Ceres Nanosciences and Bay Area Lyme Foundation.

Does Galaxy Diagnostics have an API?

No public API is recorded for Galaxy Diagnostics.

What industry is Galaxy Diagnostics in?

Galaxy Diagnostics's product category is Specialty Infectious Disease Diagnostics. Its primary akta.pro industry code is HLAFAMAD, Microbiology & Infectious Disease Testing Laboratories, with a secondary code of HLAAALAN, Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Manila TimesBay Area Lyme Ventures Invests in Galaxy Diagnostics to Advance Tick-Borne Disease TestingBay Area Lyme Ventures, an impact investment fund created by Bay Area Lyme Foundation, has made a strategic investment in Galaxy Diagnostics, a company specializing in advanced vector-borne disease testing. The investment targets the growing need for more accurate diagnostic tools as tick-borne disease cases have more than doubled in the United States over the past two decades. Galaxy Diagnostics plans to use the funding to advance research, expand access to its testing technologies, and support clinicians in diagnosing tick and vector-borne illnesses.GlobeNewswireBay Area Lyme Ventures Invests in Galaxy Diagnostics to Advance Tick-Borne Disease TestingGalaxy Diagnostics has received a strategic investment from Bay Area Lyme Ventures, the venture philanthropy fund created by Bay Area Lyme Foundation, to accelerate innovation in Lyme and tick-borne disease diagnostics. Tick-borne disease cases have more than doubled in the United States over the past two decades, underscoring the growing urgency for more accurate and accessible diagnostic tools for complex vector-borne illnesses. Galaxy Diagnostics plans to use the investment to advance research, expand access to its testing technologies, and support clinicians seeking more comprehensive diagnostic insights for patients with suspected tick and vector-borne illness.YahooBay Area Lyme Ventures Invests in Galaxy Diagnostics to Advance Tick-Borne Disease TestingGalaxy Diagnostics has secured a strategic investment from Bay Area Lyme Ventures, the impact fund established by the Bay Area Lyme Foundation. This funding aims to accelerate the development and commercialization of advanced diagnostic tools for complex tick-borne diseases, addressing a growing public health need in the United States.LymediseasePODCAST: Why Lyme disease happens to some people and not othersDr. Jennifer Miller of Galaxy Diagnostics discussed the biological complexity of Lyme disease, explaining how the Borrelia bacterium evades the immune system and causes varying symptoms among individuals. The article highlights challenges in diagnosis due to the bacterium's ability to interfere with antibody production and its tendency to migrate into tissues rather than remain in the bloodstream. It also notes that co-infections from ticks contribute to the difficulty in treating the disease.LymediseaseGalaxy Diagnostics and Virginia Tech unite in the race for a better Lyme testGalaxy Diagnostics has partnered with Virginia Tech through an exclusive license agreement for Dr. Brandon Jutras's novel peptidoglycan diagnostic target for Lyme disease, advancing to Phase 4 of the LymeX Diagnostic Prize challenge. The collaboration aims to combine Galaxy's urine antigen detection technology with Virginia Tech's peptidoglycan research to develop more reliable early-stage Lyme diagnostics for FDA submission. The partnership reunites two scientists who first met over two decades ago, with the goal of creating a noninvasive test that detects Borrelia proteins cleared through urine at earlier stages than current antibody-based tests.LymediseaseIn remembrance of Jake Picker, the “Bartonella Babe”Jake Picker, a prominent patient advocate known as the 'Bartonella Babe', passed away in California on January 20, 2024, after choosing medical aid in dying due to severe chronic illness. Galaxy Diagnostics expressed its condolences and highlighted Picker's collaborative efforts in creating educational content and patient forums regarding Bartonella infection. The company reaffirmed its commitment to advancing clinical solutions for patients in her memory.LymediseaseHer husband died from Lyme-related causes. Now she advocates for change.The article discusses the advocacy of a woman whose husband died from Lyme disease, highlighting her efforts to raise awareness and push for better diagnostic methods. She emphasizes the poor accuracy of current testing, which shows only 49-65% sensitivity, and points out the importance of direct detection methods such as the Lyme Borrelia Nanotrap® Antigen Test developed by Galaxy Diagnostics. Her journey reflects a broader push within the Lyme community for improved research and funding to combat the disease.BabsonAmanda Elam: Examining the Gender Gap in BusinessAmanda Elam, a research fellow at Babson College and CEO of Galaxy Diagnostics, discusses the persistent gender gap in business ownership and the specific challenges faced by women entrepreneurs in emerging economies. She highlights that while women start businesses at high rates in low-income countries, they face significant hurdles due to market structures, stereotypes, and lack of access to funding in male-dominated sectors.Clinical Lab ProductsGalaxy Diagnostics Launches Bartonella IFA Serology PanelGalaxy Diagnostics has launched a commercially available Bartonella IFA Serology (IgG) Panel for human health testing, which detects antibodies against four zoonotic Bartonella species. This new diagnostic tool aims to identify positive cases missed by conventional testing and serves high-risk populations such as veterinary workers. The company advocates for this panel to be used in combination with its Digital ePCR test to confirm active infections.AvmaBartonellosis: A zoonosis hidden in plain sightVeterinarians are facing increasing risks from zoonotic diseases like bartonellosis, prompting professional associations to issue updated guidelines on infection control and parasite prevention. Galaxy Diagnostics has established itself as a key provider of Bartonella testing for animals and humans through partnerships with entities like Idexx Laboratories. These developments highlight the growing recognition of vector-borne diseases as significant occupational hazards in veterinary medicine.